CCS DVT and PE: Complete Anticoagulation Guide for Step 3

SEO Title: CCS DVT PE Cases | Wells Score, CTPA, Anticoagulation Step 3 (2026)

Meta Description: Master CCS DVT and PE: Wells score, D-dimer, imaging (duplex, CTPA), anticoagulation (heparin, DOAC, warfarin), IVC filter indications.

Target Keywords: CCS DVT management, CCS PE anticoagulation, step 3 CCS DVT PE, CCS Wells score

URL Slug: ccs-dvt-pe-anticoagulation

Opening

DVT and PE cases appear consistently on Step 3 CCS exams, testing your ability to calculate pretest probability with the Wells score, interpret D-dimer results, order appropriate imaging, select anticoagulation regimens based on clinical context, and recognize massive PE requiring thrombolysis or mechanical intervention. The clinical pearl separating strong candidates is knowing that Wells score ≤2 combined with negative D-dimer essentially rules out VTE, while Wells score >2 mandates imaging regardless of D-dimer. This comprehensive guide walks you through the complete DVT/PE diagnostic and management pathway.

Clinical Pretest Probability: The Wells Score for DVT

The Wells score combines clinical findings to stratify DVT risk before testing:

Score Interpretation:

• ≤0: Low risk (1% DVT prevalence) → Negative D-dimer excludes DVT; no imaging needed

• 1-2: Low risk (2% DVT prevalence) → Negative D-dimer excludes DVT; no imaging needed

• >2: High risk (3-17% DVT prevalence depending on score) → Imaging required regardless of D-dimer

> Study Tip: Wells score mastery is essential for CCS DVT cases. The StudyCCS question bank includes 14+ DVT cases where you must calculate Wells score, interpret D-dimer strategically, and justify imaging decisions—exactly as examiners grade on exam day.

D-Dimer as a Rule-Out Test

D-dimer is a fibrin degradation product released during clot formation and lysis. It is highly sensitive (95-99%) but non-specific for VTE.

D-Dimer Interpretation Algorithm

If Wells score ≤2:

• D-dimer negative: DVT excluded; no imaging needed

• D-dimer positive: Still may order imaging if high clinical suspicion, but negative D-dimer is reassuring

If Wells score >2:

• D-dimer result is irrelevant; order imaging regardless

• Avoid false reassurance from negative D-dimer in high-probability cases

When NOT to Order D-Dimer

• Wells score >2 (image directly; D-dimer wastes time)

• Recent surgery/trauma (elevated D-dimer expected; non-specific)

• Severe liver disease (low D-dimer sensitivity)

• Active malignancy on chemotherapy (D-dimer often elevated)

• Sepsis, recent MI (elevated D-dimer; reduced specificity)

Wells Score for Pulmonary Embolism (PE)

Similar to DVT scoring, Wells score for PE guides pretest probability:

Score Interpretation:

• ≤4: Low probability (1.6% PE prevalence) → Negative D-dimer excludes PE; consider CTA only if high clinical suspicion

• 4.1-6: Intermediate probability (16-20% PE prevalence) → D-dimer testing; if negative, PE excluded; if positive, order CTA

• >6: High probability (40-50% PE prevalence) → Order CTA regardless of D-dimer; start anticoagulation while awaiting imaging

> Practice Alert: Wells score for PE is frequently tested on CCS. The StudyCCS question bank includes cases where you must calculate score, decide if D-dimer is appropriate, and justify anticoagulation initiation timing.

Diagnostic Imaging: Lower Extremity Duplex Ultrasound for DVT

Technique and Interpretation

Compression ultrasound (gold standard for DVT diagnosis):

• Normal finding: Veins fully compress with probe pressure (no clot)

• DVT finding: Vein fails to compress; echogenic thrombus visible; may see absent flow on Doppler

• Sensitivity: 95-99% for symptomatic DVT; lower for asymptomatic/calf-only DVT

Proximal vs Distal DVT

Proximal DVT (popliteal and above): High risk for PE; requires anticoagulation

Distal (calf) DVT: Low risk for PE; management is controversial:

• Some practitioners observe without anticoagulation and repeat ultrasound in 7 days

• Others anticoagulate all DVTs

• Risk of proximal progression: ~10-15% in first week

Serial Imaging

If initial duplex negative but high clinical suspicion:

• Repeat duplex in 7 days (proximal thrombi may propagate distally and become detectable)

• Alternatively, proceed to CT venography if Wells score markedly elevated

Diagnostic Imaging: CT Pulmonary Angiography for PE

Technique and Interpretation

CTPA (computed tomography pulmonary angiography):

• IV contrast through peripheral vein; imaging performed during arterial phase

• Sensitivity 94-98% for segmental and larger PE; lower for subsegmental PE

PE findings:

• Intraluminal filling defect in pulmonary artery

• "Wedge-shaped" infarct (Hampton's hump) in peripheral lung (less common; indicates pulmonary infarction from peripheral embolism)

Right Ventricular Dysfunction on CTPA

Indicates severe PE:

• RV:LV ratio >0.9 or RV dilatation

• Increases mortality risk

• May influence decision to give thrombolytics (see massive PE section below)

Risk Stratification: Provoked vs Unprovoked VTE

Provoked VTE (identifiable risk factor present):

• Major transient risk factor: Surgery, trauma, immobilization, hospitalization (duration of anticoagulation: typically 3 months)

• Example: Post-surgical DVT, trauma-related PE

Unprovoked VTE (no identifiable risk factor):

• Idiopathic thrombosis; higher recurrence risk

• Duration of anticoagulation: typically 3+ months; many require indefinite anticoagulation

• Must exclude malignancy (consider CXR, age-appropriate cancer screening)

Cancer-associated VTE:

• VTE in cancer patient = provoked with high recurrence

• Duration: Indefinite or until cancer resolved

• LMWH preferred over warfarin for cancer-related VTE (better efficacy)

Anticoagulation Selection: Heparin, DOAC, Warfarin

Initial Anticoagulation: Unfractionated Heparin (UFH) vs Low-Molecular-Weight Heparin (LMWH)

Both are acceptable for initial DVT/PE anticoagulation. Choice depends on clinical context:

Unfractionated Heparin (UFH):

• Loading: 80 units/kg IV bolus

• Maintenance: 18 units/kg/hr (titrate to aPTT 1.5-2.5 × control)

• Monitoring: aPTT at baseline, 6 hours post-loading, and after rate adjustments

• Advantages: Short half-life (1-2 hours); reversible with protamine; adjustable; used in renal failure (eGFR <30), ICU, or if pending intervention/surgery

• Disadvantages: Requires IV access, frequent lab monitoring, higher HIT (heparin-induced thrombocytopenia) risk

Low-Molecular-Weight Heparin (LMWH, e.g., Enoxaparin):

• Dosing: Enoxaparin 1 mg/kg SC Q12H or 1.5 mg/kg daily

• Advantages: Predictable kinetics; SC administration; once or twice daily dosing; lower HIT risk; weight-based dosing

• Disadvantages: Partially renally cleared (avoid if eGFR <30); not reversible (fondaparinux is alternative if HIT); less adjustable

• No monitoring required in most cases (though anti-Xa level can be checked if obesity, renal insufficiency, or dose adjustment needed)

Transition to Long-Term Anticoagulation (After 5-7 Days Initial Heparin)

Option 1: Warfarin (Vitamin K Antagonist)

Initiation:

• Start warfarin on day 1 of heparin; overlap until INR 2-3 × 2 days

• Loading dose NOT recommended (increases thrombosis risk before therapeutic INR achieved)

• Maintenance dose: 2-10 mg daily; highly variable (pharmacogenetics—CYP2C9, VKORC1)

Monitoring:

• INR at baseline, day 3-5, then weekly until stable, then monthly

• Target INR: 2-3 for DVT/PE; 2.5-3.5 if mechanical heart valve or recurrent thrombosis

Advantages: Long track record, inexpensive, oral, reversible (vitamin K, fresh frozen plasma)

Disadvantages:

• Delayed onset (5-7 days to therapeutic)

• Multiple drug/food interactions (antibiotics, NSAIDs, alcohol, cranberry juice, leafy greens)

• Narrow therapeutic window; requires frequent INR monitoring

• Teratogenic (1st trimester fetal warfarin syndrome; 2nd/3rd trimester fetal CNS effects)

Bridging consideration: If UFH or LMWH, continue for ≥5 days and until INR 2-3 × 2 days to prevent hypercoagulability during warfarin initiation (transient drop in protein C before factor II, VII, X decline).

Option 2: Direct Oral Anticoagulant (DOAC)

Advantages:

• Rapid onset (2-4 hours therapeutic)

• Fixed dosing; no monitoring required

• No bridging heparin necessary (in most cases)

• Fewer drug interactions

Specific agents:

• Apixaban (Eliquis): 5 mg BID (or 2.5 mg BID if age >60, weight <60 kg, or Cr >1.5 mg/dL)

◦ Can initiate directly (no bridging) OR after 5-7 days parenteral anticoagulation

• Rivaroxaban (Xarelto): 15 mg BID × 21 days, then 20 mg daily

◦ Some initiate directly; others prefer bridging with LMWH first

• Dabigatran (Pradaxa): Requires 5-10 days UFH or LMWH bridging before starting (no direct initiation)

◦ 150 mg BID (110 mg BID if age >75 or high bleeding risk)

• Edoxaban (Savaysa): Requires 5-10 days UFH or LMWH bridging

◦ 60 mg daily (30 mg daily if weight <60 kg or CrCl 50-95 mL/min)

Disadvantages:

• Contraindicated in severe renal failure (CrCl <15-30 depending on agent)

• Non-reversible (though reversal agents now available for apixaban/rivaroxaban)

• Less experience in pregnancy

• More expensive than warfarin

DOAC vs. Warfarin comparison:

• DOAC preferred in most outpatients (convenience, no monitoring)

• Warfarin preferred in mechanical valves, cancer-related VTE, severe renal disease

• Both equally effective for DVT/PE treatment

Fondaparinux (Factor Xa Inhibitor)

Used as an alternative to LMWH (especially if HIT):

• Dosing: Weight-based SC daily (e.g., 5 mg if <50 kg, 7.5 mg if 50-100 kg, 10 mg if >100 kg)

• Advantages: SC, once daily, predictable

• Disadvantages: Non-reversible; renally cleared (avoid if eGFR <30); less data than LMWH; expensive

• Monitoring: Anti-Xa level can be checked but rarely needed

• Transition: Use fondaparinux for initial anticoagulation (5-7 days), then transition to warfarin or DOAC

Massive PE: Thrombolysis and Mechanical Intervention

Massive PE is PE with hemodynamic instability (SBP <90 mmHg or shock).

Clinical Recognition

• Acute dyspnea, chest pain, syncope

• Hypotension, cardiogenic shock, profound hypoxemia

• RV strain on EKG (T-wave inversions V1-V3, S1Q3T3 pattern)

• RV dilatation and dysfunction on echo or CTPA

Management

Immediate steps:

1. Start heparin or fondaparinux (anticoagulation should not be delayed by imaging or discussion of thrombolytics)

2. Oxygen to maintain SaO2 >90%

3. Vasopressor support (norepinephrine) if SBP <90

4. Inotropic support (dobutamine) if RV dysfunction with low cardiac output

Thrombolytics:

• Alteplase (tPA): 100 mg IV over 2 hours (or weight-based 0.6 mg/kg if <67 kg)

◦ Alternative: 15 mg bolus, then 0.75 mg/kg over 30 min, then 0.5 mg/kg over 60 min

◦ Hemodynamically unstable PE with RV dysfunction is indication

◦ Bleeding risk significant (~10% major bleed); weigh against mortality benefit

◦ Contraindications: Active bleeding, recent surgery, intracranial pathology, severe uncontrolled hypertension

Mechanical Intervention:

• Catheter-directed thrombolysis: In interventional radiology suite; catheter placed directly into thrombus with infusion of tPA

◦ For massive PE if hemodynamic decompensation imminent or thrombolytics contraindicated

• Embolectomy: Surgical removal of thrombus; rare, reserved for fulminant cases with failed medical management

Submassive PE

Submassive PE = normotensive but with RV dysfunction and elevated troponin or BNP; intermediate risk.

Management:

• Anticoagulation (standard)

• Consider outpatient management if low bleeding risk and reliable follow-up

• Consider hospital admission if additional risk factors (e.g., borderline SBP, large PE burden on imaging)

• Thrombolytics generally NOT indicated for submassive PE (controversy; select cases may benefit)

Heparin-Induced Thrombocytopenia (HIT)

HIT is an immune-mediated thrombocytopenia induced by heparin; 1-3% of heparin-exposed patients.

Diagnosis

HIT score (4T score):

• Thrombocytopenia: Platelet count drop >50% or <100k

• Timing: Platelet drop days 5-10 of heparin (or <1 day if prior heparin exposure)

• Thrombosis: New thrombotic event (DVT, PE, stroke, MI)

• "oTher causes": Absence of alternative explanation

Score >6: High probability; confirm with HIT antibody testing (ELISA) and heparin-induced platelet aggregation (HIPA) if available

Management if HIT Suspected

1. STOP heparin immediately (all forms, including line flushes)

2. Switch anticoagulation:

◦ Direct thrombin inhibitor (DTI): Argatroban IV (start 2 mcg/kg/min; titrate to aPTT 1.5-3 × baseline)

◦ Factor Xa inhibitor: Fondaparinux SC (weight-based dosing)

3. Do NOT use warfarin alone (causes paradoxical thrombosis in acute HIT; transient protein C depletion)

4. Transition to warfarin after platelet recovery (>100k) and ≥2-3 days fondaparinux/argatroban overlap

5. Avoid future heparin exposure (document allergy in chart)

Duration of Anticoagulation

Provoked VTE (temporary risk factor):

• Minimum 3 months anticoagulation

• Risk of recurrence if anticoagulation stopped: ~2-10% (depending on severity and reversibility of risk factor)

Unprovoked VTE (idiopathic):

• Recurrence risk ~10% per year if anticoagulation stopped

• Consider indefinite anticoagulation unless high bleeding risk

• Reassess bleeding risk periodically (HAS-BLED, PRECISE-DAPT)

Cancer-related VTE:

• LMWH preferred over warfarin (better efficacy in malignancy)

• Continue anticoagulation as long as cancer active

• Many cancer centers use indefinite anticoagulation even after cancer remission

Pregnancy-related VTE:

• LMWH or UFH throughout pregnancy (avoid DOAC and warfarin teratogenicity)

• Continue through 6 weeks postpartum (extended hypercoagulable state)

• No monitoring required for LMWH in pregnancy (though some check anti-Xa levels in 3rd trimester for dose adjustment)

IVC Filter Indications

IVC filters prevent PE by trapping thrombi. Reserved for specific situations:

NOT indicated:

• Prophylaxis in high-risk patients (anticoagulation or mechanical prophylaxis preferred)

• Asymptomatic PE (no mortality benefit shown)

• Routine DVT treatment (anticoagulation standard)

Complications:

• IVC thrombosis (10-20% with permanent filters)

• Filter migration, perforation

• Recurrent DVT below filter

Removable vs. permanent:

• Removable (temporary) filters: Placed for temporary contraindications; removed within 3-6 months when possible

• Permanent filters: Placed when contraindications are long-term or indefinite; associated with higher thrombosis risk

Pregnancy and Postpartum VTE

Thromboembolism Risk in Pregnancy

Pregnancy increases VTE risk 4-5-fold:

• Hormonally-induced hypercoagulability

• Venous stasis (decreased mobility, IVC compression)

• Vessel wall injury risk (especially with cesarean delivery)

Anticoagulation in Pregnancy

Acceptable agents:

• LMWH: Safe throughout pregnancy; widely used; consistent pharmacokinetics; no fetal transfer

• UFH: Safe; used if LMWH contraindicated; may require more frequent dosing adjustments in pregnancy due to altered volume of distribution

• Fondaparinux: Emerging data suggests safety; second-line if LMWH/UFH intolerant

Contraindicated:

• Warfarin: Teratogenic in 1st trimester (fetal warfarin syndrome: nasal hypoplasia, skeletal abnormalities); CNS effects in 2nd/3rd trimester

• DOAC: Limited pregnancy data; theoretical teratogenicity risk; avoided

Postpartum Anticoagulation

• Continue LMWH or UFH through 6 weeks postpartum (extended hypercoagulability)

• Can switch to warfarin or DOAC postpartum (safe in breastfeeding)

• Duration: Typically 3+ months for provoked (pregnancy + VTE), may be indefinite if unprovoked

Inferior Vena Cava Filters in Pregnancy

Generally avoided; LMWH anticoagulation standard even in pregnancy. IVC filter reserved for rare cases with contraindication to anticoagulation.

Complete Order Set for DVT and PE Management

Suspected DVT Workup (Wells ≤2)

Labs: CBC (platelets to screen for HIT), aPTT/PT/INR (baseline)

D-dimer: If Wells ≤2, negative D-dimer rules out DVT; if positive, proceed to ultrasound

Imaging: Lower extremity compression ultrasound if Wells >2 OR D-dimer positive

Treatment: NO anticoagulation until imaging confirms DVT

Follow-up: If imaging negative and high suspicion, repeat ultrasound in 7 days

Suspected PE Workup (Wells >6)

Labs: CBC, troponin, BNP, aPTT/PT/INR, D-dimer (if Wells ≤4)

Imaging: CTPA (CTA chest with PE protocol) stat

EKG: To assess for RV strain (T-wave inversions V1-V3, S1Q3T3)

Echocardiogram: If massive PE or hemodynamic instability (assess RV function, guide thrombolytics)

Treatment: Start heparin BEFORE imaging confirmation if high suspicion and hemodynamically unstable

DVT Anticoagulation (Confirmed on Imaging)

Initial: UFH 80 units/kg bolus, then 18 units/kg/hr (monitor aPTT) OR LMWH 1 mg/kg Q12H

Check: Platelet count day 3-5 (screen for HIT); repeat if dropping

Transition (Day 5-7): Start warfarin OR DOAC (apixaban can start directly after 5-7 days heparin)

Overlap: Continue heparin until INR 2-3 × 2 days (if warfarin) or until DOAC therapeutic (5-7 days)

Duration: 3 months (provoked) to indefinite (unprovoked)

Imaging: Repeat duplex if proximal involvement to assess for propagation (controversial)

PE Anticoagulation (Confirmed on CTPA)

Initial: UFH 80 units/kg bolus, then 18 units/kg/hr (titrate aPTT) OR LMWH 1 mg/kg Q12H

Massive PE: Consider thrombolytics (alteplase 100 mg IV over 2 hours) if hemodynamically unstable

Submassive PE: Anticoagulation alone; consider ICU admission; thrombolytics controversial

Transition: Day 5-7, start warfarin or DOAC with heparin overlap

Duration: 3 months (provoked) to indefinite (unprovoked or large PE burden)

Follow-up: Outpatient anticoagulation clinic or primary care; repeat imaging NOT routine unless suspicion for recurrent PE

High-Risk DVT/PE (Cancer, Thrombophilia, Recurrent VTE)

Anticoagulation: LMWH preferred (better outcomes than warfarin in cancer)

Dosing: Enoxaparin 1.5 mg/kg daily (weight-adjusted; no monitoring)

Consider IVC filter: If recurrent VTE despite therapeutic anticoagulation; ensure adequate dosing first

Duration: Indefinite or until cancer resolved

Follow-up: Hematology/oncology comanagement; reassess bleeding risk periodically

2-Minute Screen

In the clinic or ER, prioritize:

1. Calculate Wells score (DVT or PE): Guides pretest probability and testing strategy

2. D-dimer if Wells ≤2: Negative D-dimer excludes VTE; skip imaging

3. Order imaging if Wells >2: Duplex ultrasound (DVT) or CTPA (PE) regardless of D-dimer

4. Anticoagulation timing: If high suspicion (Wells >6 for PE) and hemodynamically unstable, start heparin BEFORE imaging

5. Screen for HIT: Platelet count baseline and day 3-5 (>50% drop or <100k suggests HIT; stop heparin)

6. Choose anticoagulant: DOAC preferred in most outpatients; warfarin in mechanicalvalves/cancer; LMWH in pregnancy

Don't-Miss Diagnoses

• Massive PE: Hemodynamic instability, RV dysfunction on imaging → thrombolytics or embolectomy needed urgently

• Heparin-Induced Thrombocytopenia: Platelet drop >50% days 5-10 → stop heparin, switch to DTI or fondaparinux immediately

• Recurrent VTE Despite Anticoagulation: Ensure therapeutic levels (INR 2-3, heparin aPTT), check compliance; may need IVC filter

• IVC Thrombus with PE: Risk of sudden massive PE if thrombus dislodges; monitor closely, consider filter if high PE risk

• Superficial Thrombophlebitis: May extend to deep venous system; imaging indicated if near saphenofemoral junction

• Cancer-Related VTE: High recurrence risk; LMWH preferred; consider indefinite anticoagulation even after cancer remission

Related Articles

• CCS Pneumonia: CAP vs HAP vs VAP — Antibiotic Selection & Management

• CCS Heart Failure: Acute Decompensation vs Chronic Management

• CCS Acute Kidney Injury: Floor Management & Workup

Ready to practice? The StudyCCS question bank includes 24+ DVT and PE cases covering Wells score application, imaging interpretation, anticoagulation selection, and management of massive PE, HIT, and cancer-related thrombosis with real-time scoring. Test your VTE diagnostic and treatment skills today.